Gilead Sciences (MEX:GILD) Cyclically Adjusted FCF per Share: MXN155.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:GILD Gilead Sciences Inc MEX:GILD
72 GF Score
Price MXN2,388.13
GF Value MXN1,828.74
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Gilead Sciences Cyclically Adjusted FCF per Share?

Gilead Sciences MEX:GILD +1.41% 72 Cyclically Adjusted FCF per Share is MXN155.07 as of Jun. 2026. GuruFocus rates MEX:GILD with a GF Score™ of 72/100 and a GF Value™ of MXN1,828.74 (Significantly Overvalued). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Gilead Sciences's adjusted free cash flow per share for the three months ended in Jun. 2026 was MXN48.192. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is MXN155.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Gilead Sciences's average Cyclically Adjusted FCF Growth Rate was -4.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -0.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 5.60% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 10.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Gilead Sciences was 97.90% per year. The lowest was -0.20% per year. And the median was 25.00% per year.

As of today (2026-08-19), Gilead Sciences's current stock price is MXN2388.13. Gilead Sciences's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was MXN155.07. Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is 15.40.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 20.44. The lowest was 6.45. And the median was 10.42.


Gilead Sciences  (MEX:GILD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Gilead Sciences's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=2388.13/155.07
=15.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Gilead Sciences was 20.44. The lowest was 6.45. And the median was 10.42.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Gilead Sciences Cyclically Adjusted FCF per Share Related Terms


Gilead Sciences Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences Cyclically Adjusted FCF per Share Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 168.82 172.53 164.48 199.41 163.32

Gilead Sciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 175.96 174.79 163.32 163.22 155.07

MEX:GILD vs PFE, BMY, AMGN: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Cyclically Adjusted Price-to-FCF falls into.


MEX:GILD
72GF Score
Gilead Sciences Inc MEX:GILD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=48.192/333.9520*333.9520
=48.192

Current CPI (Jun. 2026) = 333.9520.

Gilead Sciences Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 60.577 241.428 83.792
201612 52.437 241.432 72.532
201703 40.040 243.801 54.846
201706 46.707 244.955 63.677
201709 35.292 246.819 47.751
201712 37.716 246.524 51.092
201803 28.325 249.554 37.904
201806 19.169 251.989 25.404
201809 29.267 252.439 38.717
201812 31.844 251.233 42.329
201903 20.260 254.202 26.616
201906 32.446 256.143 42.302
201909 38.097 256.759 49.551
201912 35.189 256.974 45.730
202003 23.356 258.115 30.218
202006 44.564 257.797 57.729
202009 36.702 260.280 47.090
202012 26.942 260.474 34.542
202103 39.602 264.877 49.929
202106 34.709 271.696 42.662
202109 50.737 274.310 61.769
202112 49.562 278.802 59.366
202203 25.133 287.504 29.193
202206 26.489 296.311 29.854
202209 43.165 296.808 48.567
202212 36.773 296.797 41.376
202303 23.371 301.836 25.858
202306 29.968 305.109 32.801
202309 22.629 307.789 24.553
202312 26.428 306.746 28.772
202403 28.135 312.332 30.083
202406 17.500 314.175 18.602
202409 65.446 315.301 69.317
202412 46.114 315.605 48.795
202503 26.861 319.799 28.050
202506 10.802 322.561 11.183
202509 57.944 324.800 59.577
202512 44.899 324.054 46.270
202603 34.901 330.213 35.296
202606 48.192 333.952 48.192

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of MXN155.07 mean?
Gilead Sciences (MEX:GILD) has a Cyclically Adjusted FCF per Share of MXN155.07 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' Cyclically Adjusted FCF per Share too high?
Gilead Sciences' current Cyclically Adjusted FCF per Share is MXN155.07. Overall, Gilead Sciences has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' Cyclically Adjusted FCF per Share compare to PFE and BMY?
Gilead Sciences' Cyclically Adjusted FCF per Share of MXN155.07 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current Cyclically Adjusted FCF per Share is MXN155.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (MEX:GILD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN1,828.74, compared to a current price of MXN2,388.13 — trading 30.6% above its estimated fair value. The current Cyclically Adjusted FCF per Share is MXN155.07. Gilead Sciences' overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Gilead Sciences (MEX:GILD), the current Cyclically Adjusted FCF per Share is MXN155.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (MEX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of MXN2,388.13 is trading 30.6% above its estimated GF Value™ of MXN1,828.74. GuruFocus considers Gilead Sciences to be Significantly Overvalued.

Key valuation signals for MEX:GILD:

  • Cyclically Adjusted FCF per Share: MXN155.07
  • GF Value™: MXN1,828.74 vs. price of MXN2,388.13 (30.6% above fair value)
  • GF Score™: 72/100 with 4 warning signs

No single metric tells the full story. See the MEX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
72GF Score

Get the complete analysis for MEX:GILD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,388.13
Price
MXN1,828.74
GF Value